Madrigal Pharmaceuticals, Inc.
General ticker "MDGL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.5B (TTM average)
Madrigal Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 53.0%.
Estimated limits based on current volatility of 2.1%: low 574.21$, high 599.00$
Factors to consider:
- Total employees count: 528 (+40.4%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Strategic risks and growth management, Product development risks, Manufacturing risks
- Current price 40.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [139.60$, 416.17$]
- 2025-12-31 to 2026-12-31 estimated range: [73.69$, 239.94$]
Financial Metrics affecting the MDGL estimates:
- Negative: with PPE of -13.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.97 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Inventory ratio change, % of 15.90 > 0.84
- Negative: Investing cash flow per share per price, % of -4.20 <= -0.66
Short-term MDGL quotes
Long-term MDGL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $180.13MM |
| Operating Expenses | $293.57MM | $380.50MM | $678.01MM |
| Operating Income | $-293.57MM | $-380.50MM | $-497.88MM |
| Non-Operating Income | $-1.78MM | $6.87MM | $31.98MM |
| Interest Expense | $3.96MM | $12.71MM | $14.67MM |
| R&D Expense | $245.44MM | $272.35MM | $236.72MM |
| Income(Loss) | $-295.35MM | $-373.63MM | $-465.89MM |
| Profit(Loss)* | $-295.35MM | $-373.63MM | $-465.89MM |
| Stockholders Equity | $197.39MM | $405.33MM | $754.38MM |
| Inventory | $0.00MM | $0.00MM | $34.07MM |
| Assets | $362.57MM | $640.55MM | $1,042.25MM |
| Operating Cash Flow | $-224.86MM | $-324.23MM | $-455.57MM |
| Capital expenditure | $0.22MM | $1.48MM | $1.46MM |
| Investing Cash Flow | $206.69MM | $-502.52MM | $-274.39MM |
| Financing Cash Flow | $313.45MM | $595.12MM | $735.06MM |
| Earnings Per Share** | $-17.23 | $-19.99 | $-21.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.